Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Operating activities
Net income (loss)	$ 23,037	$ (5,228)	$ 210	$ (23,376)
Adjustments to reconcile net loss used in operating activities:
Depreciation and amortization			101	115
Stock-based compensation			2,948	2,701
Acquired in-process research and development	0	0	27,641	0
Excess of initial warrant fair value over private placement proceeds	0	0	79,276	0
Change in fair value of warrant liability	(36,025)	0	(148,071)	0
Transaction costs paid pursuant to private placement			7,485	0
Contingent consideration paid pursuant to Almata Transaction			(7,500)	0
Transaction costs payable upon exercise of warrants issued in private placement			1,734	0
Change in fair value of derivative liability	1,100	(100)	6,260	120
Accretion of debt discount			0	1,828
Deferred taxes			0	23
Changes in assets and liabilities:
Other receivables			(862)	381
Inventory, net			0	20
Prepaid expenses and other assets			(2,408)	350
Lease incentive			0	158
Accounts payable			1,365	(2,094)
Accrued expenses and other liabilities			(2,110)	(8,088)
Lease liability, net			(81)	(52)
Net cash used in operating activities			(34,012)	(27,914)
Investing activities
Cash assumed from Almata Transaction			356	0
Leasehold improvements			0	(158)
Disposal of property and equipment			0	25
Net cash provided by (used in) investing activities			356	(133)
Financing activities
Proceeds from private placement investment, gross			115,625	0
Transaction costs paid pursuant to private placement			(7,485)	0
Proceeds from issuance of common stock and pre-funded warrants in underwritten public offering, net			0	13,748
Prepayment on Notes			0	(21,244)
Proceeds from issuance of common stock pursuant to ATM Program, net			0	32,470
Proceeds from issuance of common stock under employee stock purchase plan			0	67
Net cash provided by financing activities			108,140	25,041
Increase in cash, cash equivalents and restricted cash			74,484	(3,006)
Cash, cash equivalents, and restricted cash at beginning of period			7,546	13,318
Cash, cash equivalents, and restricted cash at end of period	82,030	10,312	82,030	10,312
Supplemental disclosures of cash flow information
Cash paid for interest			0	1,925
Supplemental disclosures of non-cash activities
Issuance of common stock and Series C Preferred Stock pursuant to Almata Transaction			12,272	0
Fair value of common stock retired in exchange for issuance of pre-funded warrants			0	3,640
Cash and cash equivalents	81,858	10,180	81,858	10,180
Restricted cash, current	41	1	41	1
Restricted cash, non-current	131	131	131	131
Total cash, cash equivalents and restricted cash	$ 82,030	$ 10,312	$ 82,030	$ 10,312